Cover Image

Altered mitochondrial function in MASLD: key features and promising therapeutic approaches

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), encompasses a range of liver conditions from steatosis to nonalcoholic steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights i...

Full description

Saved in:
Bibliographic Details
Main Authors: Radosavljevic, Tatjana (Author) , Brankovic, Milica (Author) , Samardzic, Janko (Author) , Djuretić, Jasmina (Author) , Vukicevic, Dusan (Author) , Vucevic, Danijela (Author) , Jakovljevic, Vladimir (Author)
Format: Article (Journal)
Language:English
Published: 26 July 2024
In: Antioxidants
Year: 2024, Volume: 13, Issue: 8, Pages: 1-18
ISSN:2076-3921
DOI:10.3390/antiox13080906
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/antiox13080906
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2076-3921/13/8/906
Get full text
Author Notes:Tatjana Radosavljevic, Milica Brankovic, Janko Samardzic, Jasmina Djuretić, Dusan Vukicevic, Danijela Vucevic and Vladimir Jakovljevic
Description
Summary:Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), encompasses a range of liver conditions from steatosis to nonalcoholic steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights its growing global impact. The pathogenesis of MASLD involves metabolic dysregulation, inflammation, oxidative stress, genetic factors and, notably, mitochondrial dysfunction. Recent studies underscore the critical role of mitochondrial dysfunction in MASLD’s progression. Therapeutically, enhancing mitochondrial function has gained interest, along with lifestyle changes and pharmacological interventions targeting mitochondrial processes. The FDA’s approval of resmetirom for metabolic-associated steatohepatitis (MASH) with fibrosis marks a significant step. While resmetirom represents progress, further research is essential to understand MASLD-related mitochondrial dysfunction fully. Innovative strategies like gene editing and small-molecule modulators, alongside lifestyle interventions, can potentially improve MASLD treatment. Drug repurposing and new targets will advance MASLD therapy, addressing its increasing global burden. Therefore, this review aims to provide a better understanding of the role of mitochondrial dysfunction in MASLD and identify more effective preventive and treatment strategies.
Item Description:Dieser Artikel gehört zum Special issue: Redox signaling in liver diseases
Gesehen am 03.03.2025
Physical Description:Online Resource
ISSN:2076-3921
DOI:10.3390/antiox13080906

Similar Items